Download PDF
Arthritis und Rheuma 2018; 38(01): 9-13
DOI: 10.1055/s-0038-1636985
Organbeteiligung bei Rheuma
Schattauer GmbH

Herzbeteiligung bei rheumatischen Erkrankungen

Heart involvement in rheumatic diseases
C. Specker
1   St. Josef-Krankenhaus/Universitätsklinikum, Essen
› Author Affiliations
Further Information

Publication History

Publication Date:
04 April 2018 (online)

    Permissions and Reprints

Zusammenfassung

Entzündlich-rheumatische Erkrankungen können als immunologische Systemerkrankungen in unterschiedlicher Häufigkeit auch zu einer Beteiligung des Herzens führen. Dabei können sämtliche kardialen Strukturen und Funktionen betroffen sein. Die Perikarditis beim Lupus, Mitralklappenfehler beim Antiphospholipidsyndrom, eine Myokarditis oder Coronariitis bei den systemischen Vaskulitiden sind typische Beispiele hierfür. Auch die Entwicklung einer pulmonalen arteriellen Hypertonie bei der Systemsklerose oder die Ausbildung eines kongenitalen AV-Blocks bei Neugeborenen von Müttern mit Lupus sind hierzu zu rechnen. Krankheits- und therapiebedingte kardiovaskuläre Sekundärschäden gewinnen im Langzeitverlauf dieser Erkrankungen zunehmende Bedeutung für Komorbidität und Mortalität.

Summary

Due to their systemic immunological character, inflammatory rheumatic diseases affect also the heart in varying frequency. All cardiac structures and functions can be involved. Typical examples are pericarditis in lupus, mitral valve thickening in antiphos- pholipid syndrome, myocarditis or coronariitis in systemic vasculitides. The development of pulmonary arterial hypertension in systemic sclerosis or the formation of a congenital AV block in newborns of mothers with lupus contribute also to cardiac involvement in rheumatic diseases.

Cardiovascular complications caused by damage of the disease and its therapy is becoming increasingly important for co-morbidity and mortality in the long-term course of chronic rheumatic diseases.

Schlüsselwörter

Herzbeteiligung - kardiale Komplikationen - rheumatische Erkrankungen - Arteriosklerose

Keywords

Cardiac involvement - cardiac complications - rheumatic diseases - atherosclerosis
 

  • Literatur

  • 1 Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 2015; 11 (12) 693-704 Epub 2015 Aug 18.
    CrossrefPubMedGoogle Scholar
  • 2 Avina-Zubieta JA, Choi HK, Sadatsafavi M. et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a metaanalysis of observational studies. Arthritis Rheum 2008; 59: 1690-1697.
    CrossrefPubMedGoogle Scholar
  • 3 Roubille C, Richter V, Starnino T. et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74: 480-489.
    CrossrefPubMedGoogle Scholar
  • 4 Jung H, Bobba R, Su J. et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010; 62 (03) 863-868.
    CrossrefPubMedGoogle Scholar
  • 5 Solomon DH, Liu CC, Kuo IH. et al. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis 2016; 75 (09) 1674-1679.
    CrossrefPubMedGoogle Scholar
  • 6 Braun J, Krüger K, Manger B. et al. Kardiovaskuläre Komorbiditäten bei entzündlich-rheumatischen Erkrankungen. Dtsch Arztebl Int 2017; 114 (12) 197-203.
    PubMedGoogle Scholar
  • 7 Gordis L. The virtual disappearance of rheumatic fever in the United States: Lessons in the rise and fall of disease. Circulation 1985; 72: 1155-1162.
    CrossrefPubMedGoogle Scholar
  • 8 van der Helm-van Mil AH. Acute rheumatic fever and poststreptococcal reactive arthritis reconsidered. Current opinion in rheumatology 2010; 22 (04) 437-442.
    CrossrefPubMedGoogle Scholar
  • 9 Goodsona NJ, Solomon DH. The cardiovascular manifestations of rheumatic diseases. Curr Opin Rheumatol 2006; 18: 135-140.
    PubMedGoogle Scholar
  • 10 Corrao S, Messina S, Pistone G. et al. Heart involvement in rheumatoid arthritis: systematic review and meta-analysis. Int J Cardiol 2013; 167 (05) 2031-2038.
    CrossrefPubMedGoogle Scholar
  • 11 Lange U, Strunk J. Kardiovaskuläre Manifestationen bei entzündlich-rheumatischen Erkrankungen. Z Rheumatol 2005; 64: 12-17.
    CrossrefPubMedGoogle Scholar
  • 12 Kobayashi Y, Giles JT, Hirano M. et al. Assessment of myocardial abnormalities in rheumatoid arthritis using a comprehensive cardiac magnetic resonance approach: a pilot study. Arthritis Research & Therapy 2010; 12 (05) R171.
    CrossrefPubMedGoogle Scholar
  • 13 Movahedian M, Afzal W, Shoja T. et al. Chest Pain Due to Pericardial Effusion as Initial Presenting Feature of Rheumatoid Arthritis: Case Report and Review of the Literature. Cardiol Res 2017; 08 (04) 161-164.
    CrossrefPubMedGoogle Scholar
  • 14 Lautermann D, Braun J. (2002) Ankylosing spondylitis – cardiac manifestations. Clinical and experimental rheumatology 2002; 06 (Suppl. 28) 11-15.
    Google Scholar
  • 15 Tselios K, Urowitz MB. Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus. Curr Rheumatol Rev 2017; 13 (03) 206-218.
    CrossrefPubMedGoogle Scholar
  • 16 Chen J, Tang Y, Zhu M, Xu A. Heart involvement in systemic lupus erythematosus: a systemic review and meta-analysis. Clin Rheumatol 2016; 35 (10) 2437-2448.
    CrossrefPubMedGoogle Scholar
  • 17 Cauduro SA, Moder KG, Tsang TS, Seward JB. Clinical and echocardiographic characteristics of hemodynamically significant pericardial effusions in patients with systemic lupus erythematosus. Am J Cardiol 2003; 92: 1370-1372.
    CrossrefPubMedGoogle Scholar
  • 18 Harris EN, Chan JKH, Asherson RA. et al. Thrombosis, recurrent fetal loss and Thrombocytopenia. Arch Intern Med 1986; 146: 2153-2156.
    CrossrefPubMedGoogle Scholar
  • 19 Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart Valve Involvement (Libman-Sacks Endocarditis) in the Antiphospholipid Syndrome. Circulation 1996; 93: 1579-1587.
    CrossrefPubMedGoogle Scholar
  • 20 Specker C, Rademacher J, Sohngen D. et al. Cerebral microemboli in patients with antiphospholipid syndrome. Lupus 1997; 06: 638-644.
    CrossrefPubMedGoogle Scholar
  • 21 Asherson RA, Harris EN, Gharavi AE, Hughes GRV. Myocardial infarction in SLE and “lupuslike” disease. Arthritis Rheum 1986; 29: 1292-1293.
    CrossrefPubMedGoogle Scholar
  • 22 Hahn BH. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med 2003; 349: 2379-2380.
    CrossrefPubMedGoogle Scholar
  • 23 Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine 1992; 71: 291-302.
    CrossrefPubMedGoogle Scholar
  • 24 Specker C, Fischer-Betz R. Gynäkologische und geburtshilfliche Probleme beim Sjögren-Syndrom. Akt Rheumatol 2005; 30: 56-58.
    Article in Thieme ConnectGoogle Scholar
  • 25 Salomonsson S, Sonesson SE, Ottosson L. et al. Ro/ SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med 2005; 201: 11-17.
    CrossrefPubMedGoogle Scholar
  • 26 Brucato A, Frassi M, Franceschini F. et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001; 44 (08) 1832-1835.
    CrossrefPubMedGoogle Scholar
  • 27 Buyon JP, Hiebert R, Copel J. et al. Autoimmuneassociated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31: 1658-1666.
    CrossrefPubMedGoogle Scholar
  • 28 Izmirly PM, Saxena A, Kim MY. et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti- SSA/Ro-associated cardiac neonatal lupus. Circulation 2011; 124 (18) 1927-1935.
    CrossrefPubMedGoogle Scholar
  • 29 Levesque K, Morel N, Maltret A. et al. “Lupus néonatal” group; Group of collaborators. Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome. Autoimmun Rev 2015; 14 (12) 1154-1160.
    CrossrefPubMedGoogle Scholar
  • 30 Saxena A, Izmirly PM, Mendez B. et al. Prevention and treatment in utero of autoimmune-associated congenital heart block. Cardiol Rev 2014; 22 (06) 263-267.
    CrossrefPubMedGoogle Scholar
  • 31 Ferri C, Valentini G, Cozzi F. et al. Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81 (02) 139-153.
    CrossrefPubMedGoogle Scholar
  • 32 Elhai M, Meune C, Boubaya M. et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017; 76 (11) 1897-1905.
    CrossrefPubMedGoogle Scholar
  • 33 Gladue H, Altorok N, Townsend W. et al. Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review. Semin Arthritis Rheum 2014; 43 (04) 536-541.
    CrossrefPubMedGoogle Scholar
  • 34 Jennette JC, Falk RJ, Bacon PA. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of vasculitides. Arthritis Rheum 2013; 65: 1-11.
    CrossrefPubMedGoogle Scholar
  • 35 Pagnoux C, Guillevin L. Cardiac involvement in small and medium-sized vessel vasculitides. Lupus 2005; 14 (09) 718-722.
    CrossrefPubMedGoogle Scholar
  • 36 Knockaert DC. Cardiac involvement in systemic inflammatory diseases. Eur Heart J 2007; 28 (15) 1797-1804.
    CrossrefPubMedGoogle Scholar
  • 37 Misra DP, Shenoy SN. Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk. Rheumatol Int. 2016 Feb 17. [Epub ahead of print].
    PubMedGoogle Scholar